All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 68 points (0.4%) at 17,604 as of Tuesday, March 29, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,037 issues advancing vs. 895 declining with 166 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the industry include

Celgene

(

CELG

), down 1.1%, and

Gilead

(

GILD

), down 0.9%. Top gainers within the industry include

Alkermes

(

ALKS

), up 6.4%,

Mylan

(

MYL

), up 2.5%,

Sanofi

(

SNY

), up 2.4%,

Illumina

(

ILMN

), up 2.1% and

Teva Pharmaceutical Industries

(

TEVA

), up 1.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Biomarin Pharmaceutical

(

BMRN

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Biomarin Pharmaceutical is down $1.99 (-2.5%) to $77.01 on light volume. Thus far, 684,513 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $76.42-$79.93 after having opened the day at $79.01 as compared to the previous trading day's close of $79.00.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $13.1 billion and is part of the health care sector. Shares are down 24.6% year-to-date as of the close of trading on Monday. Currently there are 13 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Biomarin Pharmaceutical

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Biomarin Pharmaceutical Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Novartis

(

NVS

) is down $1.05 (-1.4%) to $72.08 on heavy volume. Thus far, 2.4 million shares of Novartis exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $71.11-$72.16 after having opened the day at $71.60 as compared to the previous trading day's close of $73.13.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. Novartis has a market cap of $174.0 billion and is part of the health care sector. Shares are down 15.0% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate Novartis a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Novartis

as a

hold

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

Novartis Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Vertex Pharmaceuticals

(

VRTX

) is down $1.14 (-1.4%) to $77.56 on light volume. Thus far, 716,310 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $76.79-$78.61 after having opened the day at $78.59 as compared to the previous trading day's close of $78.70.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases. Vertex Pharmaceuticals has a market cap of $19.9 billion and is part of the health care sector. Shares are down 37.5% year-to-date as of the close of trading on Monday. Currently there are 11 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Vertex Pharmaceuticals

as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full

Vertex Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).